Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
作者： Sverre E Kjeldsen , Björn Dahlöf , Richard B Devereux , Stevo Julius , Peter Aurup
关键词:
摘要: Results Blood pressure was reduced by 28/9 and mm Hg in the losartan atenolol arms. The main outcome 25% with compared atenolol, 25.1 vs 35.4 events per 1000 patient-years (relative risk [RR], 0.75; 95% confidence interval [CI], 0.56-1.01; P=.06, adjusted for degree of ECG-LVH; unadjusted RR, 0.71; CI, 0.53-0.95; P=.02). Patients receiving had reductions following without a difference incidence myocardial infarction: cardiovascular mortality (8.7 16.9 patient-years; 0.54; 0.34-0.87; P=.01), nonfatal fatal stroke (10.6 18.9 0.60; 0.38-0.92; P=.02), new-onset diabetes (12.6 20.1 0.62; 0.40-0.97; P=.04), total (21.2 30.2 0.72; 0.53-1.00; P=.046). Losartan decreased ECG-LVH more than (P.001) better tolerated. Conclusion These data suggest that is superior to treatment patients isolated systolic hypertension ECG-LVH. JAMA. 2002;288:1491-1498 www.jama.com
sci-hub.se 参考文章(33)
Björn Dahlöf, Kjell Pennert, Lennart Hansson, Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. American Journal of Hypertension. ,vol. 5, pp. 95- 110 ,(1992) , 10.1093/AJH/5.2.95
S. E. Kjeldsen, B. Dahlof, R. B. Devereux, S. Julius, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel, , Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study American Journal of Hypertension. ,vol. 13, pp. 899- 906 ,(2000) , 10.1016/S0895-7061(00)00280-6
Stanley Lemeshow, David W. Hosmer, Applied Logistic Regression ,(1989)
D Levy, M Salomon, R B D'Agostino, A J Belanger, W B Kannel, Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. ,vol. 90, pp. 1786- 1793 ,(1994) , 10.1161/01.CIR.90.4.1786
Lars H Lindholm, Hans Ibsen, Björn Dahlöf, Richard B Devereux, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Stevo Julius, Sverre E Kjeldsen, Krister Kristiansson, Ole Lederballe-Pedersen, Markku S Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Peter Aurup, Jonathan Edelman, Steven Snapinn, None, Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. ,vol. 359, pp. 1004- 1010 ,(2002) , 10.1016/S0140-6736(02)08090-X
John K. Kjekshus, Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. American Journal of Cardiology. ,vol. 57, ,(1986) , 10.1016/0002-9149(86)90888-X
William B. Kannel, Systolic Blood Pressure, Arterial Rigidity, and Risk of Stroke JAMA. ,vol. 245, pp. 1225- 1229 ,(1981) , 10.1001/JAMA.1981.03310370017013
Hans R Brunner, Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. American Journal of Cardiology. ,vol. 87, pp. 3- 9 ,(2001) , 10.1016/S0002-9149(01)01538-7
Christopher G. Isles, Louise M. Walker, Gareth D. Beevers, Irene Brown, Helen L. Cameron, John Clarke, Victor Hawthorne, David Hole, Anthony F. Lever, James W.K. Robertson, Jean A. Wapshaw, Mortality in patients of the Glasgow Blood Pressure Clinic. Journal of Hypertension. ,vol. 4, pp. 141- 156 ,(1986) , 10.1097/00004872-198604000-00003
Ola Samuelsson, Cardiovascular Morbidity in Relation to Change in Blood Pressure and Serum Cholesterol Levels in Treated Hypertension JAMA. ,vol. 258, pp. 1768- 1776 ,(1987) , 10.1001/JAMA.1987.03400130082038